Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR)

Kessler, David S.; MacNeill, Stephanie J.; Tallon, Deborah; Lewis, Glyn; Peters, Tim J.; Hollingworth, William; Round, Jeff; Burns, Alison; Chew-Graham, Carolyn A.; Anderson, Ian M.; Shepherd, Tom; Campbell, John; Dickens, Chris M.; Carter, Mary; Jenkinson, Caroline; Macleod, Una; Gibson, Helen; Davies, Simon; Wiles, Nicola J.

doi:10.1136/bmj.k4218

All Outputs (1)

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR) (2018)
Journal Article
Kessler, D. S., MacNeill, S. J., Tallon, D., Lewis, G., Peters, T. J., Hollingworth, W., Round, J., Burns, A., Chew-Graham, C. A., Anderson, I. M., Shepherd, T., Campbell, J., Dickens, C. M., Carter, M., Jenkinson, C., Macleod, U., Gibson, H., Davies, S., & Wiles, N. J. (2018). Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR). BMJ, 363, Article k4218. https://doi.org/10.1136/bmj.k4218

Objective: To investigate the effectiveness of combining mirtazapine with Serotonin-Noradrenaline Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants for patients in primary care who had not responded to an anti... Read More about Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: Phase III randomised placebo controlled trial (MIR).